Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.40% | -9.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.93% | 21.17% | |||
| Operating Income | 19.93% | -21.17% | |||
| Income Before Tax | 44.95% | -50.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.95% | -50.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.95% | -50.37% | |||
| EBIT | 19.93% | -21.17% | |||
| EBITDA | 19.95% | -21.19% | |||
| EPS Basic | 47.76% | -35.23% | |||
| Normalized Basic EPS | 47.76% | -35.15% | |||
| EPS Diluted | 47.76% | -35.23% | |||
| Normalized Diluted EPS | 47.76% | -35.15% | |||
| Average Basic Shares Outstanding | 5.46% | 11.28% | |||
| Average Diluted Shares Outstanding | 5.46% | 11.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||